ArticleLancet (London, England)2017
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015.
Article in Lancet (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 903 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Airway Microbiome and Th17-mediated Inflammation in COPD Among HIV-infected Individuals in a Rural Ugandan Cohort
Evaluation of the Effectiveness of a Very Brief Smoking Cessation Intervention in Family Health Centers: A Pragmatic Randomized Controlled Trial
Who cites it
903 citing papers in PubMed, 4 syntheses or guidelines pooled it, 2,040 citations in OpenAlex.
- Expression Analysis, Diagnostic and Prognostic Accuracy of microRNAs in Oral Cancer: An Overview With Meta-Analysis.International dental journal · 2026Pooled it
- Comparative disease risks associated with cigarette smoking and use of moist smokeless tobacco and snus: an umbrella review of epidemiological evidence from the United States and Western Europe.BMC public health · 2025Pooled it
- Comparison of smokers' mortality with non-smokers following out-of-hospital cardiac arrests: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2024Pooled it
- Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods.BMC cancer · 2024Pooled it
- Intraoperative PEEP Strategy and Postoperative Pulmonary Complications in Obese Patients: A Randomized Trial with Exploratory Analysis of Smoking Status.Medical sciences (Basel, Switzerland) · 2026Trial
- Combined Smoking Cessation and Alcohol Abstinence Treatment for People Experiencing Homelessness: A Randomized Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- intEgrating Smoking Cessation treatment As part of usual Psychological care for dEpression and anxiety (ESCAPE): A randomised and controlled, multi-centre, acceptability and feasibility trial with nested qualitative methods.Addiction (Abingdon, England) · 2025Trial
- Effectiveness of a Mobile Phone-Delivered Multiple Health Behavior Change Intervention (LIFE4YOUth) in Adolescents: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Boosting Smoking Cessation Intervention Utilization in Chinese Health Care Providers: A Randomized Controlled Trial of the "WeChat WeQuit" Medical Education Program.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Trial
- Trial
- Text Message-Based Cessation Intervention for People Who Smoked or Used Smokeless Tobacco in India: A Feasibility Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Trial
- Standardized Manual-Based Smoking Cessation Treatment in Patients With Comorbid Mental Disorders: Qualitative Interview Study.JMIR formative research · 2026Article
- Proteomic analysis of plasma and extracellular vesicles from subjects with impaired vascular health.Bioscience reports · 2026Article
- Simultaneous versus Sequential Cessation of Tobacco and Cannabis: Preferences of Young Adults Who Co-Use in France.Drug and alcohol review · 2026Article
- Sex and socioeconomic inequalities in global asthma burden attributable to major risk factors, 1990-2021.Journal of thoracic disease · 2026Article
- Article
- Polydatin mitigates cigarette smoke-induced pulmonary apoptosis by regulating Bim via FoxO3 post-translational modifications and modulating the gut microenvironment.Biology direct · 2026Article
- A decade of increasing complexity in patients sustaining a hip fracture in England, Wales and Northern Ireland: a national cohort study using the National Hip Fracture Database dataset.Age and ageing · 2026Article
- Global, Regional, and National Burden of Caries Among Women of Childbearing Age From 1990 to 2021 and Prediction.International dental journal · 2026Article
- Association Between Cigarette Smoking and Early Improvement in Lower Urinary Tract Symptoms After 180-W GreenLight Photoselective Vaporization of the Prostate: Findings From a Dual-Center Study.International journal of urology : official journal of the Japanese Urological Association · 2026Article
843 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author at 13 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe scale-up of tobacco control, especially after the adoption of the Framework Convention for Tobacco Control, is a major public health success story. Nonetheless, smoking remains a leading risk for early death and disability worldwide, and therefore continues to require sustained political commitment. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) offers a robust platform through which global, regional, and national progress toward achieving smoking-related targets can be assessed.
methodsWe synthesised 2818 data sources with spatiotemporal Gaussian process regression and produced estimates of daily smoking prevalence by sex, age group, and year for 195 countries and territories from 1990 to 2015. We analysed 38 risk-outcome pairs to generate estimates of smoking-attributable mortality and disease burden, as measured by disability-adjusted life-years (DALYs). We then performed a cohort analysis of smoking prevalence by birth-year cohort to better understand temporal age patterns in smoking. We also did a decomposition analysis, in which we parsed out changes in all-cause smoking-attributable DALYs due to changes in population growth, population ageing, smoking prevalence, and risk-deleted DALY rates. Finally, we explored results by level of development using the Socio-demographic Index (SDI).
findingsWorldwide, the age-standardised prevalence of daily smoking was 25·0% (95% uncertainty interval [UI] 24·2-25·7) for men and 5·4% (5·1-5·7) for women, representing 28·4% (25·8-31·1) and 34·4% (29·4-38·6) reductions, respectively, since 1990. A greater percentage of countries and territories achieved significant annualised rates of decline in smoking prevalence from 1990 to 2005 than in between 2005 and 2015; however, only four countries had significant annualised increases in smoking prevalence between 2005 and 2015 (Congo [Brazzaville] and Azerbaijan for men and Kuwait and Timor-Leste for women). In 2015, 11·5% of global deaths (6·4 million [95% UI 5·7-7·0 million]) were attributable to smoking worldwide, of which 52·2% took place in four countries (China, India, the USA, and Russia). Smoking was ranked among the five leading risk factors by DALYs in 109 countries and territories in 2015, rising from 88 geographies in 1990. In terms of birth cohorts, male smoking prevalence followed similar age patterns across levels of SDI, whereas much more heterogeneity was found in age patterns for female smokers by level of development. While smoking prevalence and risk-deleted DALY rates mostly decreased by sex and SDI quintile, population growth, population ageing, or a combination of both, drove rises in overall smoking-attributable DALYs in low-SDI to middle-SDI geographies between 2005 and 2015.
interpretationThe pace of progress in reducing smoking prevalence has been heterogeneous across geographies, development status, and sex, and as highlighted by more recent trends, maintaining past rates of decline should not be taken for granted, especially in women and in low-SDI to middle-SDI countries. Beyond the effect of the tobacco industry and societal mores, a crucial challenge facing tobacco control initiatives is that demographic forces are poised to heighten smoking's global toll, unless progress in preventing initiation and promoting cessation can be substantially accelerated. Greater success in tobacco control is possible but requires effective, comprehensive, and adequately implemented and enforced policies, which might in turn require global and national levels of political commitment beyond what has been achieved during the past 25 years.
fundingBill & Melinda Gates Foundation and Bloomberg Philanthropies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.